Abstract
TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Current Molecular Medicine
Title: Differential TNF-Signaling in Chronic Inflammatory Disorders
Volume: 4 Issue: 4
Author(s): Martin H. Holtmann and Markus F. Neurath
Affiliation:
Keywords: tnf, tnf-r2, signal transduction, inflammatory disorders
Abstract: TNF-α is a pleiotropic cytokine with strong proinflammatory and immunomodulatory properties. TNF-α plays a critical role in many acute or chronic inflammatory diseases and anti-TNFstrategies have proven to be clinically effective. Two TNF-specific cell surface receptors TNF-R1 and TNF-R2 have been identified and the function of these receptors and the downstream intracellular signal transduction pathways have been extensively studied in vitro. For a long time TNF-R1 was considered to be the predominant mediator of TNF-signaling, whereas TNF-R2 was ascribed only auxilliary function. However, there is increasing clinical and experimental evidence for an important independent role of p80 signaling in chronic inflammatory conditions. It is conceivable that the multiple TNF-mediated chronic inflammatory disorders differ in terms of the ligand form (soluble TNF-α versus membrane bound TNF-α), the receptor (TNF-R1 versus TNF-R2) and the downstream signaling cascades utilized. The elucidation of the specific characteristics of TNF-signaling in distinct inflammatory disorders will lead to a better understanding ot the pathogenesis of these diseases and will be the basis for the development of more specific and more efficient therapeutic approaches.
Export Options
About this article
Cite this article as:
Holtmann H. Martin and Neurath F. Markus, Differential TNF-Signaling in Chronic Inflammatory Disorders, Current Molecular Medicine 2004; 4 (4) . https://dx.doi.org/10.2174/1566524043360636
DOI https://dx.doi.org/10.2174/1566524043360636 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview
Current Drug Targets Stem Cell Therapies
Recent Patents on Regenerative Medicine Reported Dose as a Measure of Drug Exposure after Paracetamol Overdose in Children
Current Clinical Pharmacology Novel Insights in the Metabolic Syndrome-induced Oxidative Stress and Inflammation-mediated Atherosclerosis
Current Cardiology Reviews BRCA-FA Pathway as a Target for Anti-Tumor Drugs
Anti-Cancer Agents in Medicinal Chemistry Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease
Current Medicinal Chemistry Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies
Current Bioactive Compounds CuAAC Click Chemistry Accelerates the Discovery of Novel Chemical Scaffolds as Promising Protein Tyrosine Phosphatases Inhibitors
Current Medicinal Chemistry Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A
Cardiovascular & Hematological Disorders-Drug Targets Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Hyaluronic Acid: Targeting Immune Modulatory Components of the Extracellular Matrix in Atherosclerosis
Current Medicinal Chemistry Antibacterial Function of the Human Cathelicidin-18 Peptide (LL-37) between Theory and Practice
Protein & Peptide Letters Beneficial Effects of Traditional Chinese Medicine on the Treatment of Osteoporosis on Ovariectomised Rat Models
Current Drug Targets Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Safety Assessment of Tretinoin Loaded Nano Emulsion and Nanostructured Lipid Carriers: A Non-invasive Trial on Human Volunteers
Current Drug Delivery The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine
Current Molecular Medicine Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Current Cancer Drug Targets ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Current Bioactive Compounds